image description

Tag: Lilly

Baricitinib Development as a Lupus Treatment Discontinued

January 28, 2022 The Lupus Research Alliance is disappointed that the Phase 3 development program of  OLUMIANT® (baricitinib) as a potential treatment for adults with systemic lupus erythematosus (SLE) has been discontinued. The drug’s manufacturer Lilly made this decision based on results from two Phase 3 trials (SLE-BRAVE-I and II).  While SLE-BRAVE-I showed a significant […] Read More

Promising News from Major Medical Meeting, EULAR

Updated June 5, 2020 One of the largest meetings for rheumatologists went virtual this year to enable scientists from around the world to share their latest findings amid the COVID-19 pandemic. EULAR, the e-Congress of the European League Against Rheumatism, runs June 3 -6, and LRA is pleased to share promising results from clinical trials […] Read More

Updates in Lupus Clinical Research from the LUPUS 2019 Meeting

April 11, 2019 The Lupus Research Alliance is pleased to share the results from four clinical trials presented at LUPUS 2019.  These studies continue to push our way forward toward new and improved treatments to help the lupus community. There’s a Silver Lining in New Belimumab Results Jim Oates, MD, Medical University of South Carolina, […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates